Daily Endocrinology Research Analysis
Analyzed 80 papers and selected 3 impactful papers.
Summary
Three impactful endocrinology papers stand out today: a rigorously conducted RCT in low-resource settings shows no advantage of insulin glargine over human isophane insulin for pediatric type 1 diabetes; a mechanistic study identifies adipocyte-derived OX40L as a targetable checkpoint driving insulin resistance; and a meta-analysis links GLP-1 receptor agonists to fewer major limb events in type 2 diabetes with PAD.
Research Themes
- Value-based diabetes care in low-resource settings
- Immunometabolic checkpoints in obesity-driven insulin resistance
- Cardio-limb outcomes with incretin-based therapies
Selected Articles
1. Human versus analogue insulin for children and young adults with type 1 diabetes in low-resource settings (HumAn-1): a multicentre, open-label, randomised controlled trial.
In 400 youths with type 1 diabetes in Bangladesh and Tanzania, insulin glargine did not reduce time in very low range nor improve time in range versus human isophane/premixed insulin over 6 months. Serious adverse events were uncommon and similar across groups, supporting human insulin as a viable basal option in low-resource settings.
Impact: This pre-registered multicentre RCT provides high-quality, policy-relevant evidence for basal insulin selection in LMICs, highlighting equivalence on key CGM metrics and enabling value-based allocation.
Clinical Implications: For pediatric T1D in low-resource settings, human isophane/premixed insulin remains an appropriate basal choice when cost and access are prioritized, without compromising CGM-defined safety. Glargine may be reserved for individualized indications.
Key Findings
- Time in very low range was similar: 3.6% (SD 5.6) with glargine vs 3.4% (4.3) with usual care; adjusted mean difference 0.22% (97.5% CI −0.83 to 1.27; p=0.63).
- Time in target range was similar: 40.5% (18.4) vs 38.1% (18.1); adjusted mean difference 0.55% (97.5% CI −2.78 to 3.89; p=0.71).
- Serious adverse events were uncommon (6 SAEs in 5/199 glargine participants vs 14 SAEs in 13/201 usual care participants).
Methodological Strengths
- Randomised, multicentre trial in LMIC settings with blinded CGM outcome assessment.
- Pre-specified coprimary CGM endpoints and clinical registration (ClinicalTrials.gov NCT05614089).
Limitations
- Open-label design may influence behaviours despite blinded CGM.
- Six-month follow-up may miss longer-term differences; conducted in specific LMIC contexts limiting generalizability.
Future Directions: Cost-effectiveness analyses, pragmatic implementation trials integrating supply-chain realities, and longer follow-up to assess severe hypoglycaemia, DKA, and quality-of-life endpoints.
BACKGROUND: Human insulins including intermediate-acting human insulin (ie, isophane insulin) remain widely used for children and young people with type 1 diabetes, especially in low-resource settings. We aimed to assess whether insulin glargine reduces the risk of serious hypoglycaemia or improves time in range when compared against human isophane insulin among children and young people with type 1 diabetes in low-income and middle-income countries.
METHODS: HumAn-1 was a randomised, open label, parallel-group trial conducted at one site in Bangladesh and two sites in Tanzania. Participants aged 7-25 years with a clinical diagnosis of type 1 diabetes were randomly assigned (1:1) to receive insulin glargine (Basaglar, Eli Lilly, Indianapolis, IN, USA) or to continue usual care (ie, isophane insulin or premixed 70/30) for basal insulin coverage.
2. Adipocyte OX40L promotes adipose T cell activation and insulin resistance in obesity.
Adipocyte-derived OX40L is strongly upregulated in obesity and drives Th1 accumulation, adipose inflammation, and insulin resistance. Genetic deletion in adipocytes or systemic OX40 deficiency, as well as anti-OX40L antibody blockade, improved insulin sensitivity without altering adiposity, nominating OX40L as an immunometabolic checkpoint.
Impact: This study reveals a previously unrecognized adipocyte–T cell co-stimulatory axis as a causal driver of insulin resistance and demonstrates druggability via antibody blockade.
Clinical Implications: Although preclinical, targeting adipocyte OX40L could enable tissue-specific immunotherapy to mitigate insulin resistance and metabolic inflammation without affecting body weight.
Key Findings
- Adipocyte OX40L is markedly upregulated in obesity and elevated in adipocytes from obese humans.
- Adipocyte-specific OX40L deletion or global OX40 deficiency reduces visceral adipose Th1 cells, attenuates inflammation, and improves insulin sensitivity without changing adiposity.
- Therapeutic anti-OX40L antibody reproduces metabolic benefits; Th1 cell transfer reverses protection, confirming mechanism.
- Macrophage-specific OX40L deletion had no metabolic impact, pinpointing adipocytes as the critical source.
Methodological Strengths
- Integrated approach: transcriptomic profiling, mouse genetics (cell-type-specific deletion), antibody blockade, and T cell transfer.
- Human relevance supported by elevated OX40L in adipocytes from obese individuals.
Limitations
- Preclinical models; translational efficacy and safety of OX40L blockade in humans remain untested.
- Potential systemic immune effects of OX40/OX40L pathway modulation require careful evaluation.
Future Directions: Evaluate OX40L blockade in metabolic disease models with comorbidities, develop adipose-targeted delivery, and assess biomarkers of response for early-phase clinical translation.
T cells contribute critically to obesity-induced adipose inflammation and insulin resistance, yet the co-stimulatory signals that govern their activation in adipose tissue remain unclear. Here, we systematically profile co-stimulatory molecules in adipocytes and adipose tissue macrophages and identify OX40 ligand (OX40L) as the most robustly upregulated in obesity. OX40L is also elevated in adipocytes from obese humans. Although macrophage-specific OX40L deletion has no metabolic impact, global OX40 deficiency or adipocyte-specific OX40L deletion reduces Th1 cell accumulation in visceral adipose tissue, attenuates inflammation and improves insulin sensitivity without affecting adiposity. These benefits are reversed by Th1 cell transfer. Therapeutic blockade of OX40L with a neutralizing antibody mimics the protective effects of genetic deletion. Our findings identify adipocyte-derived OX40L as a critical mediator of obesity-associated immune dysfunction and establish it as a targetable checkpoint for tissue-specific immunotherapy in metabolic disease.
3. Glucagon-like peptide-1 receptor agonists and major limb events in adults with type 2 diabetes and peripheral artery disease: a systematic review and meta-analysis of RCTs and cohort studies.
Across 12 studies (13 arms; 418,282 participants), GLP-1RAs were associated with a 27% lower risk of major limb events and reduced risks of amputation, revascularization, gangrene, MACE, and all-cause mortality. Findings were robust across sensitivity analyses, underscoring potential limb-protective benefits in T2D with PAD.
Impact: This synthesis links GLP-1RAs to clinically meaningful limb outcomes beyond glycaemia, informing therapy selection in a high-risk group where evidence had been sparse.
Clinical Implications: In T2D with PAD, GLP-1RAs may be preferred when aiming to reduce limb events and mortality, while advocating for trials with standardized limb endpoints to confirm causality.
Key Findings
- GLP-1RA therapy reduced major limb events (RR 0.73, 95% CI 0.65–0.82).
- Lower risks observed for LEA (RR 0.76), revascularization (RR 0.81), gangrene (RR 0.80), MACE (RR 0.76), and all-cause mortality (RR 0.67).
- Subgroup and sensitivity analyses yielded consistent estimates; effect robust across study designs.
Methodological Strengths
- Large aggregate sample (418,282) across RCTs and well-matched cohorts.
- Comprehensive analyses including leave-one-out sensitivity and meta-regression.
Limitations
- Heterogeneity in limb event definitions and inclusion of observational designs introduce residual confounding.
- Agent-specific effects and dose-response could not be fully resolved.
Future Directions: Conduct dedicated RCTs with standardized limb-specific endpoints in PAD, head-to-head comparisons across GLP-1RAs, and mechanistic studies on limb perfusion and wound healing.
BACKGROUND: The impact of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on peripheral artery disease (PAD) remains uncertain. We assessed the association between GLP-1RA use and major limb events in individuals with type 2 diabetes (T2D) and PAD. METHODS: We performed a literature search from inception to 31 March 2026 for randomized controlled trials and cohort studies comparing GLP-1RA use versus placebo, active comparators or non-use on lower limb outcomes in individuals with T2D and PAD. The primary outcome was a composite of major limb events, as defined by the investigators of the original studies included in the meta-analysis. Secondary outcomes included lower extremity amputation (LEA), revascularization, gangrene, major adverse cardiovascular events (MACE) and all-cause mortality. Subgroup analyses, leave-one-out sensitivity analyses, and meta-regression analysis were also performed.